Epizyme Unternehmenskultur

Mr. Matthew E. Ros, also known as Matt, has been the Chief Operating Officer of Epizyme, Inc. since May 6, 2016. Mr. Ros served as Senior Vice President of Commercial Operations at Ariad Pharmaceuticals Inc., since January 2009. He served as Vice President of Commercial Operations at Ariad Pharmaceuticals Inc., from August 2008 to January 2009. He served as Vice President of Oncology Marketing at Ariad Pharmaceuticals Inc., from November 2007 to August 2008. He was responsible for planning and leading the U.S. launch of deforolimus with colleagues from Merck & Co., Inc., and preparing the market for ARIAD's growing pipeline of oncology products, including its new multi-targeted kinase inhibitor, AP24534. He joined Ariad in 2007. He has more than 25 years of experience in sales, marketing, franchise strategy and operations leadership in both global pharmaceutical and early-stage biotechnology companies. He held a series of senior positions at Bristol-Myers Squibb Company (BMS). He served as Senior Director and U.S. Commercial Lead at Bristol-Myers Squibb. He played a key role in the launch and commercialization of BMS's oncology products, ixabepilone (Ixempra(TM)) and dasatinib (Sprycel???), as well as the early development of cetuximab (Erbitux???). He served on the Board of Trustees of CancerCARE. Mr. Ros received his B.Sc. from the State University of New York.

Dr. H. Robert Horvitz, Ph.D., M.D. serves as Venture Partner and Co-Chairman of Medical and Scientific Advisory Board at MPM BioVentures IV, L.P. Dr. Horvitz is a Co-Founder and Board Observer of KEW Group LLC. He is the co-founder of Epizyme, Inc. and serves as its Chairman of the Scientific Advisory Board. He has been Chair of Scientific Advisory Board at PureTech Health plc since November 30, 2015 and serves as its Board Advisor. Dr. Horvitz is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology, an Investigator of the Howard Hughes Medical Institute, Neurobiologist (Neurology) and Geneticist (Medicine) at Massachusetts General Hospital and a member of the M.I.T. McGovern Institute for Brain Research and the M.I.T. Koch Institute for Integrative Cancer Research. He co-founded Idun Pharmaceuticals, Inc. in 1993 and served as its Chairman of Scientific Advisory Board. He co-founded NemaPharm, Inc. He served as a Venture Partner MPM Capital. He served as a Senior Partner, Advisor of PureTech Health PLC. He served as a Neurobiologist and Geneticist at the Massachusetts General Hospital. He was elected to the United States National Academy of Sciences in 1991. Previously, Dr. Horvitz was an Assistant Professor, an Associate Professor at the Massachusetts Institute of Technology. He was appointed an Investigator at the McGovern Institute for Brain Research in 2001. He joined the MIT Department of Biology faculty in 1978. He was named Whitehead Professor of Biology in 1999 and David H. Koch Professor of Biology in 2000. He was the President of the Genetics Society of America in 1995. He serves as the Chair of the Scientific Advisory Board of Enlight Biosciences LLC. Dr. Horvitz is a member of the Board of Trustees of the Massachusetts General Hospital and is Chairman of the Board of Trustees of the Society for Science and the Public. He serves as a Co-Chairman of the Working Group on Preclinical Models for Cancer of the National Cancer Institute. Dr. Horvitz serves as Member of Medical and Scientific Advisory Board at MPM Capital. He serves as a Member of Medical Advisory Board at Gairdner Foundation He serves as a Member of Scientific Advisory Board at Mitobridge, Inc. and AVEO Pharmaceuticals, Inc. He has served on many Editorial Boards. He is a recipient of the Gairdner Foundation International Award, the Alfred P. Sloan, Jr. Prize from the General Motors Cancer Research Foundation and the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience. He is a Fellow of the American Academy of Arts and Sciences and of the American Academy of Microbiology. Dr. Horvitz received the U.S. National Academies of Science Award in Molecular Biology; the Charles A. Dana Award for Pioneering Achievements in Health; the Ciba-Drew Award for Biomedical Science; the General Motors Cancer Research Foundation Alfred P. Sloan, Jr. Prize; the Gairdner Foundation International Award; the March of Dimes Prize in Developmental Biology; the Genetics Society of America Medal; the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience; the Wiley Prize in the Biomedical Sciences; the Peter Gruber Foundation Genetics Prize; the American Cancer Society Medal of Honor; the Alfred G. Knudson Award of the National Cancer Institute; and the U.K. Genetics Society Mendel Medal. He has received the 2002 Nobel Prize in Physiology and Medicine for discovering and characterizing genes that controlling programmed cell death (apoptosis), findings that have provided the basis for understanding many aspects of human biology and disease. Dr. Horvitz received a Ph.D. in Biology from Harvard University in 1974 and a B.S. in Mathematics and Economics from the Massachusetts Institute of Technology.

Richard Chesworth serves as the Senior Vice President Research of Epizyme. Richard started at Epizyme in January of 2016. Richard currently resides in Greater Boston Area.

Pamela Strode serves as the Senior Vice President, Regulatory Affairs and Quality Assurance of Epizyme. Pamela started at Epizyme in September of 2016. Pamela currently resides in Greater Boston Area.

John Bishop serves as the Senior Vice President - Chemistry, Manufacturing, & Controls of Epizyme. John started at Epizyme in May of 2017. John currently resides in Greater Boston Area.

Julian Fowler serves as the Vice President of Information Technology of Epizyme. Julian started at Epizyme in May of 2015. Julian currently resides in Greater Boston Area.